Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021694 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL15459 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL11785505 | 1.00 | MEN1 (0.55) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL1759752 | 0.95 | — | — | |
| SCHEMBL27950186 | 0.83 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL31229193 | 0.83 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28054987 | 0.81 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7919973 | 0.79 | MEN1 (0.61) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL15253392 | 0.78 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3214310 | 0.78 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109651275-A | Novel compound in triazine class, its composition and preparation method thereof | 优缔新材料科技(苏州)有限公司 | 2019-04-19 | — | — | CN | disclosed |
| US-9956291-B2 | Nanoformulation and methods of use of thyroid receptor beta1 agonists for liver targeting | MOUSA SHAKER A (US) | 2018-05-01 | — | — | US | disclosed |
| EP-1273917-B1 | Acridinium ester labels having hydrophilic modifiers | SIEMENS HEALTHCARE DIAGNOSTICS (US) | 2014-05-07 | — | — | EP | disclosed |
| US-20140017329-A1 | NANOFORMULATION AND METHODS OF USE OF THYROID RECEPTOR BETA1 AGONISTS FOR LIVER TARGETING | MOUSA SHAKER A (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2011159951-A2 | TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2011-12-22 | — | — | WO | disclosed |
| US-20110311616-A1 | TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-12-22 | — | — | US | disclosed |
| CN-101379037-A | Solid Phase Synthesis of Acridine Derivatives | SIEMENS MEDICAL SOLUTIONS DIAG (US) | 2009-03-04 | — | — | CN | disclosed |
| US-6664043-B2 | Detectable chemiluminescent acridinium ester label, comprising an acridinium ester with a hydrophilic modifier | BAYER CORPORATION | 2003-12-16 | — | — | US | disclosed |
| US-20030045716-A1 | Acridinium ester labels having hydrophilic modifiers | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2003-03-06 | — | — | US | disclosed |
| EP-1273917-A2 | Acridinium ester labels having hydrophilic modifiers | Bayer Corporation (US) | 2003-01-08 | — | — | EP | disclosed |
| US-3996269-A | USEFUL AS TEXTILE TREATING AGENTS, FROM GLYCOL AMINES AND UREA | ICI UNITED STATES INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3981913-A | TEXTILE TREATING AGENTS, CHEMICAL INTERMEDIATES | ICI UNITED STATES INC. (US) | 1976-09-21 | — | — | US | disclosed |
| US-3965072-A | Polyurea-urethane polymers from urea, diamines and aminoalcohols | ICI UNITED STATES INC. (US) | 1976-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045716-A1 | Acridinium ester labels having hydrophilic modifiers | SRM, SMS, ACR | MEN1 2049/4885KMT2A 2995/4885TSHR 664/4885 |
| US-20110311616-A1 | TARGETING TUMOR ASSOCIATED MACROPHAGES USING BISPHOSPHONATE-LOADED PARTICLES | BPGM, CD209, CD47 | MEN1 165/4885KMT2A 3889/4885TSHR 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.